Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald, Philippe Gabríel Steg, Jaime A. Davidson, Boaz Hirshberg, Peter Öhman, Robert Frederich, Stephen D. Wiviott, Elaine Hoffman, Matthew A. Cavender, Jacob A. Udell, Nihar R. Desai, Ofri Mosenzon, Darren K. McGuire, Kausik K. Ray, Lawrence A. Leiter, Itamar Raz

New England Journal of Medicine, 2013

Harvard University, Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group, VA Boston Healthcare System, Université Paris Cité, The University of Texas Southwestern Medical Center, Southwestern Medical Center, Hôpital Bichat-Claude-Bernard, Inserm, AstraZeneca (United States), Bristol-Myers Squibb (United States), Hadassah Academic College, St George's, University of London, University of Toronto, St. Michael's Hospital

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

3451

Citations

View on Google Scholar

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Abstract

Journal Details

Join JournalsHub

Welcome Back